Effects of Supplementation of Vitamin D in Patients With Crohn's Disease

June 27, 2018 updated by: Lorena Nagme de Oliveira Pinto, Federal University of Juiz de Fora

The Impact of Serum Vitamin D and Calcium Levels on the Body Composition, Bone Mineral Density, Muscle Strength, Exercise Tolerance, Fatigue and Inflammatory Activity in Patients With Crohn's Disease: a Randomized Controlled Trial

Thus, the aim of the current study is to assess the influence of vitamin D deficiency and, consequently, of serum calcium deficiency in the body composition, muscular activity, bone mineral density, fatigue, and exercise tolerance of CD patients. Secondly, it also aims to determine the impact of vitamin D supplementation on this population.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

This will be a clinical, randomized, controlled, and double-blind trial comprising a consecutive sample of 110 CD patients in remission and low serum vitamin D levels treated by the Gastroenterology team of the Inflammatory Intestinal Disease Clinic at the University Hospital (HU/CAS), Federal University of Juiz de Fora (UFJF). These patients will be divided into two groups with 55 patients each. One group will receive vitamin D supplementation (50.000 UI/week) and the other will receive placebo. Upon the approval by the Ethics Committee of the UFJF, the study aims and procedures will be previously explained to the individuals, who will sign an informed consent form.

The sample size was based on the handgrip strength test, assuming an alpha risk of 5 % and beta risk of 80 %, standard deviation of 2.5, and a difference in magnitude of 30% of response between intervention and placebo group, the sample size needed was 45 patients in each group. Therefore, considering potential losses, 55 patients will be recruited for each group, requiring a total of 110 volunteers.

Study procedure

Phase 1. Assessment All patients in the study will be subjected to the following tests: a. clinical assessment; B. biochemical assessment; c. body composition assessment/anthropometry; d. bone mineral density assessment; e. peripheral muscle strength assessment; f. fatigue assessment; g.Exercise Tolerance Testing

Clinical Assessment of the Disease The following data will be collected in the initial assessment: age, gender, CD duration, data related to the Montreal Classification (age at the time of diagnosis, disease behavior and location), glucocorticoid use and number of exacerbations in the previous year. The inflammatory activity assessment will be held according to the Harvey-Bradshaw Index, When the score is less than 5, the disease is considered to be inactive.

Biochemical Assessment The participants will be instructed to fast 12 hours prior to the blood sampling for analysis. A 5 ml venous blood sample will be collected from the patients in order to determine biochemical parameters. The University Hospital routine laboratory will analyze the venous blood, the levels of C-reactive protein (CRP), calcium, 25-hydroxyvitamin D, parathyroid hormone (PTH) and inflammatory cytokines such as Interleukins (IL) 17, IL 6 and Tumor necrosis factor alfa (TNF-α) . CRP and serum calcium are routinely evaluated in all CD patients under follow-up in the inflammatory bowel disease clinic at HU/CAS.

The following reference values will be taken into consideration regarding 25-hydroxyvitamin D: < 20ng/mL = deficiency, between 21 and 29 ng/mL = insufficiency, and > 30 ng/mL = satisfactory.

Bone Mineral Density Assessment A bone densitometer, Lunar Prodigy Primo (pr + 351035), will be used to measure the patients' bone mineral density (BMD), expressed in g/cm2, by dual-energy x-ray absorptiometry (DXA). The double-energy X-ray densitometry of the skeleton or specific sites such as the spine and the hip is based on the X-rays absorption by the calcium crystals in the bone. The lumbar spine regions between L1 and L4 and those of the total proximal femur will be assessed. The examination will be held under appropriate conditions, according to the technical quality controls. The coefficient of variation for the lumbar spine and total proximal femur will be obtained based on these results. The low BMD will be defined by the reduction greater than -2.0 standard deviations from the reference value mean of healthy individuals, adjusted according to height, age and gender (Z score), in compliance with the official positions of the International Society for Clinical Densitometry (ISCD).

Body Composition Assessment/Anthropometry The assessment will be held through the Quantum BIA (bioelectrical impedance analysis) bioimpedance device. The device is four-pole, has digital display, and provides resistance and reactance values. Total and segmental body composition parameters will be also assessed by DXA expressed in kg.

Muscle Strength Assessment The peripheral muscle strength will be assessed through the maximum voluntary handgrip strength using hand-held dynamometry (HHD), which consists of a simple and objective test that estimates the skeletal muscle function. The Jamar's hydraulic dynamometer will be used, since it is recommended by the American Society of Hand Therapists (ASHT) and is considered the most accurate and precise instrument used to assess HHD .

Fatigue Assessment The questionnaire by Chalder et al. (Annex), which was validated in Brazil will be applied to assess fatigue.

Exercise Tolerance Testing The exercise capacity is assessed by the walking test with progressive loading or Shuttle Walk Test.

Phase 2. Intervention A double-blind, randomized, placebo-controlled study will be performed. After the evaluation of serum vitamin D levels, patients with vitamin D below 30ng/mL will be randomized into two groups. One group will receive supplementation with cholecalciferol (vitamin D3) tablets and the other group will receive placebo. Those will be provided at no cost to the patients. The dosage of 1.500-2.000 IU (International Units) vitamin D/day is recommended in order to meet the need of vitamin D above 30ng/mL in adults. However, a dose at least 2 to 3 times higher is recommended for CD patients due to malabsorption, significant loss of adipose tissue and use of glucocorticoids. Thus, the dose of 50,000IU/week will be administered in a single dose.

The contraindications and precautions on the use of vitamin D will be respected, namely: hypersensitivity to the D-group vitamins, hypercalcemia, hypercalciuria and metastatic calcification; and interactions with digitalis, thiazides, and anticonvulsant and antacid medications.

Despite the possible interference of the skin melanin concentration in vitamin D absorption, no evidence was found to support the differentiated supplementation between Afro descendant and Caucasian individuals.

The patients drawn to the placebo group will receive inert content tablets without therapeutic effect. After the study completion, these control patients will receive complete treatment for hypovitaminosis D.

Throughout the intervention phase, both the treated group and the control group patients will be monitored by phone every 15 days in order to optimize their adhesion.

Phase 3. Reassessment At the end of 6 months of supplementation with cholecalciferol (vitamin D3), this subgroup of patients will be subjected to the same assessments performed in phase 1.

Study Type

Interventional

Enrollment (Anticipated)

110

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Brazil
    • Minas Gerais
      • Juiz de Fora, Minas Gerais, Brazil
        • Universidade Federal de Juiz de Fora

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Clinical diagnosis of Crohn's Disease (moderate to severe)
  • Remission of Crohn's activity
  • Reduced blood levels of vitamin D

Exclusion Criteria:

  • Presence of other chronic concomitant disease
  • Presence of other autoimmune disease
  • Presence of sleep disturbance
  • Abuse of alcohol and other drugs
  • Pregnancy or lactation, climacteric and/or menopausal women
  • Adherence to extreme diet (e.g. macrobiotic or vegetarian diet)
  • Celiac disease
  • Presence of extensive resection of the small intestine (more than 100cm²)
  • Patients undergoing vitamin D replacement for the last 6 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: QUADRUPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Vitamin D
Tablets with 50000UI cholecalciferol (vitamin D3) will be administered, weekly, for six months.
Dietary supplement: Vitamin D
investigate the relationship between musculoskeletal manifestations, in Crohn population, and the hypovitaminosis D
PLACEBO_COMPARATOR: Placebo
The patients selected to the placebo group will receive inert content tablets without therapeutic effect, weekly, for six months.
Other: Placebo
compare the musculoskeletal manifestations of the Placebo group with the group receiving Vitamin D

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Increase in the grip strength in patients with Crohn under vitamin D supplementation
Time Frame: After 6 months of supplementation with vitamin D
Grip strength will be expressed in kg
After 6 months of supplementation with vitamin D

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Increase in mineral bone density (MBD)
Time Frame: After 6 months of supplementation with vitamin D
MBD assessed by DXA, expressed in gr/cm²
After 6 months of supplementation with vitamin D
Decrease in fecal Calprotectin levels
Time Frame: After 6 months of supplementation with vitamin D
Levels of calprotectin under 200µg/g
After 6 months of supplementation with vitamin D
Global reduction in laboratorial inflammatory biomarkers (TNF-α)
Time Frame: After 6 months of supplementation with vitamin D
TNF-α expressed in pg/ml
After 6 months of supplementation with vitamin D
Increase in exercise capacity assessed by Shuttle Walk Test (SWT)
Time Frame: After 6 months of supplementation with vitamin D
Improvement in the distance achieved in the SWT expressed in meters (m)
After 6 months of supplementation with vitamin D
Increase in lean body mass in patients with Crohn under vitamin D supplementation
Time Frame: After 6 months of supplementation with vitamin D
Body mass will be assessed by DXA and will be expressed in kg
After 6 months of supplementation with vitamin D
Reduction in fatigue perception in patients with Crohn under vitamin D supplementation
Time Frame: After 6 months of supplementation with vitamin D
Fatigue will be measured by the Chalder Fatigue Questionnaire (CFQ). The CFQ is analyzed by 2 domains physical and mental (cutoff: patient's total score higher than 2)
After 6 months of supplementation with vitamin D
Global reduction in laboratorial inflammatory biomarkers (IL 6)
Time Frame: After 6 months of supplementation with vitamin D
IL 6 expressed in pg/ml
After 6 months of supplementation with vitamin D
Global reduction in laboratorial inflammatory biomarkers (IL 17)
Time Frame: After 6 months of supplementation with vitamin D
IL 17 expressed in pg/ml
After 6 months of supplementation with vitamin D
Global reduction in laboratorial inflammatory biomarkers (CRP)
Time Frame: After 6 months of supplementation with vitamin D
CRP expressed in mg/dl
After 6 months of supplementation with vitamin D

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Federal University of Juiz de Fora

Collaborators

Fundação de Amparo à Pesquisa do estado de Minas Gerais

Investigators

  • Principal Investigator: Júlio MF Chebli, Professor, Federal University of Juiz de Fora

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

December 1, 2016

Primary Completion (ANTICIPATED)

August 1, 2020

Study Completion (ANTICIPATED)

February 1, 2022

Study Registration Dates

First Submitted

February 24, 2016

First Submitted That Met QC Criteria

March 9, 2016

First Posted (ESTIMATE)

March 10, 2016

Study Record Updates

Last Update Posted (ACTUAL)

June 29, 2018

Last Update Submitted That Met QC Criteria

June 27, 2018

Last Verified

April 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CAAE41674814500005147

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fatigue

Clinical Trials on Vitamin D

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe